Indapta, founded in 2017 and headquartered in San Francisco, is a biotech company focused on harnessing the power of the immune system to treat hematologic and solid cancers. Their allogeneic platform, based on g-NK cells deficient in the FceR1g protein, can effectively kill cancer cells when combined with monoclonal antibodies. By developing a proprietary, first-in-class, non-engineered and allogeneic G-NK cell therapy, Indapta aims to provide a universal treatment option for cancer patients.